Home
Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainstemline.com

Year Founded2003

Employees51 - 200

Annual Revenue$25M - $50M

Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. (including company regionals)

stemline.com

See more website traffic and engagement information

Stemline Therapeutics, Inc. Revenue up to May 2026 is 25M - 50M

revenue generated by Stemline Therapeutics, Inc. top domains

Stemline Therapeutics, Inc. top domains revenue over 3 years

Revenue for Stemline Therapeutics, Inc. top domains

stemline.com25M - 50M

See more with Sales Intelligence

Total visits to Stemline Therapeutics, Inc.'s top domains

Understand Stemline Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

stemline.com7.6K

See more with Sales Intelligence

Avg. visit duration in Stemline Therapeutics, Inc.'s top domains

Analyze Stemline Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

stemline.com00:00:34

See more with Sales Intelligence

Avg. pageviews on Stemline Therapeutics, Inc.'s top domains

See how Stemline Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

stemline.com2.77

See more with Sales Intelligence

Stemline Therapeutics, Inc. top competitors by domain

Top similar sites in May 2026, ranked by their affinity

vitals.comCompany NameVitalsEmployees51 - 200HQUnited States, New Jersey, LyndhurstAnnual revenue$25M - $50MTotal visits1MHealth > Medicine

Top technologies used by Stemline Therapeutics, Inc.

These are the website technologies, by industry, used by Stemline Therapeutics, Inc. top domains

Widget (4)

Twemoji

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Mobile (2)

Meta Viewport

More Technologies

9

See all

News & Signals from Stemline Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsStemline Therapeutics, Inc. attended event The European Hematology Association (EHA) 2026 Congress on Jun 14th '26.FLORENCE, Italy and NEW YORK, June 14, 2026 /CNW/ - The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral[i] at The European Hematology Association (EHA) 2026 Congress.

NewsStemline Therapeutics, Inc. attended event 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 25th '26.FLORENCE, Italy and NEW YORK, May 25, 2026 /CNW/ - The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and tagraxofusp will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

NewsTheall left Stemline Therapeutics, Inc. as Vice President of Clinical Development - Breast Cancer on Mar 1st '26.Most recently, Dr. Theall served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini, where she led clinical strategy and execution supporting the FDA approval of ORSERDU(TM)(elacestrant) in 2023 and subsequent global approvals.